Impact of Lipodystrophy on the prevalence and components of metabolic syndrome in HIV-infected patients

BMC Infectious Diseases

Volumn 11, Issue , 2011, Pages

  Freitas, Paula ^a   Carvalho, Davide ^a   Souto, Selma ^a   Santos, Ana C ^a,b   Xerinda, Sandra ^c   Marques, Rui ^c   Martinez, Esteban ^d   Sarmento, António ^a   Medina, José L ^a  

^a University of Porto   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c Centro Hospitalar Universitário de São João   (Portugal)

^d UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Cardiovascular Risk; HIV infection; Lipodystrophy; Metabolic syndrome

Indexed keywords

ANTIRETROVIRUS AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; AGE DISTRIBUTION; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FEMALE; FRAMINGHAM RISK SCORE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRIGLYCERIDEMIA; ISCHEMIC HEART DISEASE; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PREVALENCE; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; WAIST CIRCUMFERENCE; CHEMICALLY INDUCED DISORDER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; MIDDLE AGED;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HUMANS; LIPODYSTROPHY; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREVALENCE;

EID: 80053175900     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-11-246     Document Type: Article

References (42)

1. Aberg JA. Cardiovascular complications in HIV management: past, present, and future. J Acquir Immune Defic Syndr 2009, 50(1):54-64. 10.1097/QAI.0b013e31818ceaa4, 2746916, 19295335.
2. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, Cooper DA. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998, 12(7):F51-58. 10.1097/00002030-199807000-00003, 9619798.
3. Saint-Marc T, Partisani M, Poizot-Martin I, Rouviere O, Bruno F, Avellaneda R, Lang JM, Gastaut JA, Touraine JL. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study. AIDS 2000, 14(1):37-49. 10.1097/00002030-200001070-00005, 10714566.
4. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002, 288(21):2709-2716. 10.1001/jama.288.21.2709, 12460094.
5. Mancia G, Facchetti R, Bombelli M, Polo Friz H, Grassi G, Giannattasio C, Sega R. Relationship of office, home, and ambulatory blood pressure to blood glucose and lipid variables in the PAMELA population. Hypertension 2005, 45(6):1072-1077. 10.1161/01.HYP.0000165672.69176.ed, 15867138.
6. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen MR, Groop L. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001, 24(4):683-689. 10.2337/diacare.24.4.683, 11315831.
7. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2005, 48(9):1684-1699. 10.1007/s00125-005-1876-2, 16079964.
8. Greenland P. Critical questions about the metabolic syndrome. Circulation 2005, 112(24):3675-3676. 10.1161/CIRCULATIONAHA.105.583310, 16344398.
9. Worm SW, Sabin CA, Reiss P, El-Sadr W, Monforte A, Pradier C, Thiebaut R, Law M, Rickenbach M, De Wit S, Lundgren JD, Friis-Moller N. Presence of the metabolic syndrome is not a better predictor of cardiovascular disease than the sum of its components in HIV-infected individuals: data collection on adverse events of anti-HIV drugs (D:A:D) study. Diabetes Care 2009, 32(3):474-480. 10.2337/dc08-1394, 2646032, 19056612.
10. Mangili A, Jacobson DL, Gerrior J, Polak JF, Gorbach SL, Wanke CA. Metabolic syndrome and subclinical atherosclerosis in patients infected with HIV. Clin Infect Dis 2007, 44(10):1368-1374. 10.1086/516616, 2745593, 17443477.
11. Gazzaruso C, Sacchi P, Garzaniti A, Fratino P, Bruno R, Filice G. Prevalence of metabolic syndrome among HIV patients. Diabetes Care 2002, 25(7):1253-1254. 10.2337/diacare.25.7.1253, 12087038.
12. Jerico C, Knobel H, Montero M, Ordonez-Llanos J, Guelar A, Gimeno JL, Saballs P, Lopez-Colomes JL, Pedro-Botet J. Metabolic syndrome among HIV-infected patients: prevalence, characteristics, and related factors. Diabetes Care 2005, 28(1):132-137. 10.2337/diacare.28.1.132, 15616246.
13. Jacobson DL, Tang AM, Spiegelman D, Thomas AM, Skinner S, Gorbach SL, Wanke C. Incidence of metabolic syndrome in a cohort of HIV-infected adults and prevalence relative to the US population (National Health and Nutrition Examination Survey). J Acquir Immune Defic Syndr 2006, 43(4):458-466. 10.1097/01.qai.0000243093.34652.41, 16980905.
14. Estrada V, Martinez-Larrad MT, Gonzalez-Sanchez JL, de Villar NG, Zabena C, Fernandez C, Serrano-Rios M. Lipodystrophy and metabolic syndrome in HIV-infected patients treated with antiretroviral therapy. Metabolism 2006, 55(7):940-945. 10.1016/j.metabol.2006.02.024, 16784968.
15. Wand H, Calmy A, Carey DL, Samaras K, Carr A, Law MG, Cooper DA, Emery S. Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. AIDS 2007, 21(18):2445-2453. 10.1097/QAD.0b013e3282efad32, 18025881.
16. Mondy K, Overton ET, Grubb J, Tong S, Seyfried W, Powderly W, Yarasheski K. Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population. Clin Infect Dis 2007, 44(5):726-734. 10.1086/511679, 3170426, 17278068.
17. Samaras K, Wand H, Law M, Emery S, Cooper D, Carr A. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia. Diabetes Care 2007, 30(1):113-119. 10.2337/dc06-1075, 17192343.
18. Bonfanti P, Giannattasio C, Ricci E, Facchetti R, Rosella E, Franzetti M, Cordier L, Pusterla L, Bombelli M, Sega R, Quirino T, Mancia G. HIV and metabolic syndrome: a comparison with the general population. J Acquir Immune Defic Syndr 2007, 45(4):426-431. 10.1097/QAI.0b013e318074ef83, 17514013.
19. Adeyemi O, Rezai K, Bahk M, Badri S, Thomas-Gossain N. Metabolic syndrome in older HIV-infected patients: data from the CORE50 cohort. AIDS Patient Care STDS 2008, 22(12):941-945. 10.1089/apc.2008.0119, 19072100.
20. Diehl LA, Dias JR, Paes AC, Thomazini MC, Garcia LR, Cinagawa E, Wiechmann SL, Carrilho AJ. [Prevalence of HIV-associated lipodystrophy in Brazilian outpatients: relation with metabolic syndrome and cardiovascular risk factors]. Arq Bras Endocrinol Metabol 2008, 52(4):658-667. 10.1590/S0004-27302008000400012, 18604379.
21. Sobieszczyk ME, Hoover DR, Anastos K, Mulligan K, Tan T, Shi Q, Gao W, Hyman C, Cohen MH, Cole SR, Plankey MW, Levine AM, Justman J. Prevalence and predictors of metabolic syndrome among HIV-infected and HIV-uninfected women in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr 2008, 48(3):272-280. 10.1097/QAI.0b013e31817af461, 18545157.
22. Nicola Squillace GO AR, Chiara S, Stefano Z, Giula N, Barabara B, Roberto E, Giovanni G. Metabolic syndrome in HIV-associated lipodystrophy. HAART and correlated pathologies 2008, 1:35-38.
23. Palella F, WZ CH. Correlates of the metabolic syndrome among HIV seropositive and seronegative men in the multicenter AIDS Cohort Study. Denver 2006,
24. Lichtenstein KA. Redefining lipodystrophy syndrome: risks and impact on clinical decision making. J Acquir Immune Defic Syndr 2005, 39(4):395-400. 10.1097/01.qai.0000167478.28051.3a, 16010159.
25. Bacchetti P, Gripshover B, Grunfeld C, Heymsfield S, McCreath H, Osmond D, Saag M, Scherzer R, Shlipak M, Tien P. Fat distribution in men with HIV infection. J Acquir Immune Defic Syndr 2005, 40(2):121-131. 10.1097/01.qai.0000182230.47819.aa, 3166344, 16186728.
26. Santos AC, Barros H. Impact of metabolic syndrome definitions on prevalence estimates: a study in a Portuguese community. Diab Vasc Dis Res 2007, 4(4):320-327. 10.3132/dvdr.2007.059, 18158702.
27. Van Maldergem L, Da Silva H, Freitas P, D' Abronzo FH. Berardinelli-Seip Syndrome: a new Portuguese disease?. Eur J Hum Genet 1998, (6):74A.
28. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC, Spertus JA, Costa F. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112(17):2735-2752. 10.1161/CIRCULATIONAHA.105.169404, 16157765.
29. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome--a new worldwide definition. Lancet 2005, 366(9491):1059-1062. 10.1016/S0140-6736(05)67402-8, 16182882.
30. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97(18):1837-1847.
31. Carr A, Samaras K, Chisholm DJ, Cooper DA. Abnormal fat distribution and use of protease inhibitors. Lancet 1998, 351(9117):1736.
32. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999, 353(9170):2093-2099. 10.1016/S0140-6736(98)08468-2, 10382692.
33. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998, 351(9119):1881-1883. 10.1016/S0140-6736(98)03391-1, 9652687.
34. Capeau J, Magre J, Lascols O, Caron M, Bereziat V, Vigouroux C. [Primary lipodystrophies]. Ann Endocrinol (Paris) 2007, 68(1):10-20.
35. Garg A. Acquired and inherited lipodystrophies. N Engl J Med 2004, 350(12):1220-1234. 10.1056/NEJMra025261, 15028826.
36. Mallon PW, Unemori P, Sedwell R, Morey A, Rafferty M, Williams K, Chisholm D, Samaras K, Emery S, Kelleher A, Cooper DA, Carr A. In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA. J Infect Dis 2005, 191(10):1686-1696. 10.1086/429697, 15838796.
37. Friis-Moller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P, Thiebaut R, Morfeldt L, De Wit S, Pradier C, Calvo G, Law MG, Kirk O, Phillips AN, Lundgren JD. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003, 349(21):1993-2003.
38. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005, 352(1):48-62. 10.1056/NEJMra041811, 15635112.
39. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002, 287(3):356-359. 10.1001/jama.287.3.356, 11790215.
40. Amorosa V, Synnestvedt M, Gross R, Friedman H, MacGregor RR, Gudonis D, Frank I, Tebas P. A tale of 2 epidemics: the intersection between obesity and HIV infection in Philadelphia. J Acquir Immune Defic Syndr 2005, 39(5):557-561.
41. Ena J, Benito C, Llacer P, Pasquau F, Amador C. [Abnormal body fat distribution and type of antiretroviral therapy as predictors of cardiovascular disease risk in HIV-infected patients]. Med Clin (Barc) 2004, 122(19):721-726.
42. De Socio GV, Parruti G, Quirino T, Ricci E, Schillaci G, Adriani B, Marconi P, Franzetti M, Martinelli C, Vichi F, Penco G, Sfara C, Madeddu G, Bonfanti P. Identifying HIV patients with an unfavorable cardiovascular risk profile in the clinical practice: results from the SIMONE study. J Infect 2008, 57(1):33-40. 10.1016/j.jinf.2008.03.007, 18436307.